Fulgent Genetics (NASDAQ:FLGT) Releases FY 2025 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of -0.650--0.650 for the period, compared to the consensus earnings per share estimate of -0.460. The company issued revenue guidance of $310.0 million-$310.0 million, compared to the consensus revenue estimate of $324.2 million. Fulgent Genetics also updated its FY25 guidance to $(0.65) EPS.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on FLGT. Piper Sandler cut their target price on Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating for the company in a research note on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a "hold" rating to a "sell" rating in a research note on Wednesday, November 27th.

Fulgent Genetics Price Performance

Shares of FLGT stock traded down $0.17 during trading hours on Monday, reaching $15.28. 568,179 shares of the company's stock were exchanged, compared to its average volume of 195,173. The company has a market cap of $467.37 million, a P/E ratio of -2.77 and a beta of 1.39. The company's 50 day moving average is $17.25 and its two-hundred day moving average is $19.38. Fulgent Genetics has a 1 year low of $14.92 and a 1 year high of $25.11.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.